<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02446730</url>
  </required_header>
  <id_info>
    <org_study_id>BEAUTY-II</org_study_id>
    <nct_id>NCT02446730</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome</brief_title>
  <acronym>BEAUTY-II</acronym>
  <official_title>A Prospective, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of 5mg Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Who Underwent Percutaneous Coronary Intervention With BiomatrixTM Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chonnam National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of 5mg maintenance dose (MD)
      of prasugrel in patients with acute myocardial infarction (AMI) who underwent percutaneous
      coronary intervention (PCI) with BiomatrixTM stent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About 1400 patients derived from Korean patients with acute coronary syndrome (ACS) receiving
      percutaneous coronary intervention (PCI) with BES(Biolimus-eluting stent, BiomatrixTM) in a
      routine manner will be enrolled in the investigators trial.

      These patients will be randomized 1:1 to either prasugrel 5mg once daily MD or clopidogrel
      75mg once daily MD after successful PCI with BES .

      The investigators excluded the patients with age ≥75 years, body weight &lt;60 kg, or history of
      TIA (transient ischemic attack) or stroke. Follow-up data will be collected until 1-year
      after index procedure.

      Primary efficacy end-point defined as the composite of cardiac death, non-fatal MI, stent
      thrombosis and ischemic driven target vessel revascularization and safety end-points as BARC
      (the Bleeding Academic Research Consortium) type ≥ 2 bleeding.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A compoiste of cardiac death, non-fatal myocardiac infarction and stroke</measure>
    <time_frame>within the 1 year after BIOMATRIXTM Stent implantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>within the 1 year after BIOMATRIXTM Stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>within the 1 year after BIOMATRIXTM Stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-fatal myocardial infarction</measure>
    <time_frame>within the 1 year after BIOMATRIXTM Stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>within the 1 year after BIOMATRIXTM Stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>within the 1 year after BIOMATRIXTM Stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent thrombosis</measure>
    <time_frame>within the 1 year after BIOMATRIXTM Stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BARC bleeding 2,3,and 5</measure>
    <time_frame>within the 1 year after BIOMATRIXTM Stent implantation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1400</enrollment>
  <condition>Cardiac Death</condition>
  <condition>Hemorrhage</condition>
  <condition>Cerebrovascular Accident</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>BES with Prasugel 5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biolimus-eluting stent with Prasugrel 5mg once daily MD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BES with Clopidogrel 75mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biolimus-eluting stent with Clopidogrel 75mg once daily MD</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BES (biodegradable polymer biolimus-eluting stent)</intervention_name>
    <description>BES implantation</description>
    <arm_group_label>BES with Prasugel 5mg</arm_group_label>
    <arm_group_label>BES with Clopidogrel 75mg</arm_group_label>
    <other_name>BiomatirxTM</other_name>
    <other_name>Biomatrix FlexTM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugel</intervention_name>
    <arm_group_label>BES with Prasugel 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <arm_group_label>BES with Clopidogrel 75mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who can undergo percutaneous coronary intervention with Biomatrix stent with
             no history of TIA or stroke,

          -  75 years old or younger,

          -  body weight of 60 kg or more and diagnosed with acute coronary syndrome

        Exclusion Criteria:

          -  Patients with history of TIA or stroke,

          -  75 years old or older,

          -  body weight of 60 kg or under,

          -  hypersensitivity to or contraindicated for heparin, aspirin, clopidogrel, prasugrel or
             contrast media
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myung Ho Jeong, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Myung-Ho Jeong, PhD</last_name>
    <phone>+82-062-220-5114</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Jung-Me Lee</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung-Ho , Jeong</last_name>
      <phone>+82-62-220-5114</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2015</study_first_submitted>
  <study_first_submitted_qc>May 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2015</study_first_posted>
  <last_update_submitted>May 15, 2015</last_update_submitted>
  <last_update_submitted_qc>May 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonnam National University Hospital</investigator_affiliation>
    <investigator_full_name>Myung Ho Jeong</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Death</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

